PRE-MARKET
Pfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical products. The company is planning $2.5 billion in cost-saving measures expected to be in place by 2029. With a focus on innovative treatments, Pfizer aims to reduce reliance on older, high-grossing medications and looks forward to a notable growth revival post-2028, activel….
Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts
Impact Score
Market Sentiment
→NeutralPrimary Sectors
Pfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical products. The company is planning $2.5 billion in cost-saving measures expected to be in place by 2029. With a focus on innovative treatments, Pfizer aims to reduce reliance on older, high-grossing medications and looks forward to a notable growth revival post-2028, activel…
Key Highlights
Pfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical products.
The company is planning $2.5 billion in cost-saving measures expected to be in place by 2029.
With a focus on innovative treatments, Pfizer aims to reduce reliance on older, high-grossing medications and looks forward to a notable growth revival post-2028, activel….
Source
Economic Times
Published
4h ago
Impact Score
75 / 100
Category
Corporate Earnings
Moderate near-term volatility expected while markets assess implications for Corporate Earnings.
What this means
No linked events found.